Literature DB >> 8532023

Polymorphism of adhesion molecule CD31 and its role in acute graft-versus-host disease.

E Behar1, N J Chao, D D Hiraki, S Krishnaswamy, B W Brown, J L Zehnder, F C Grumet.   

Abstract

BACKGROUND: Graft-versus-host disease (GVHD) caused by poorly defined minor (i.e., other than HLA) histocompatibility antigens remains a serious problem in recipients of bone marrow transplants. We sought to determine whether the CD31 adhesion molecule is a minor alloantigen.
METHODS: We directly sequenced samples of complementary DNA (cDNA) encoding CD31 molecules from 21 unrelated normal subjects. Sequence-specific primers were then designed to amplify alleles by the polymerase chain reaction, thereby permitting CD31 typing of genomic DNA from additional normal subjects. To assess the relevance of CD31 matching to bone marrow transplantation, we performed CD31 typing of 46 recipients of bone marrow (32 without GVHD and 14 with severe [grade III or IV] acute GVHD) and their HLA-identical sibling donors. The immunoreactivity of CD31 phenotypes with anti-CD31 monoclonal antibodies was compared by flow cytometry.
RESULTS: Direct sequencing of cDNA for CD31 from the 21 normal subjects identified a single polymorphism, CTG-->GTG (Leu-->Val), at codon 125; we designated the resulting alleles CD31.L and CD31.V, respectively. The CD31 genotypes of these and 142 other unrelated subjects were of the expected frequencies. Among the transplant recipients, 71 percent of those with acute GVHD had CD31 genotypes that were not identical to the donor's genotype, as compared with 22 percent of the recipients without GVHD (P = 0.004). The binding of anti-CD31 monoclonal antibodies as measured by fluorescence-activated cell sorting correlated with the CD31 types of homozygous cell lines.
CONCLUSIONS: The adhesion molecule CD31 is polymorphic. When donor and recipient genotypes are not identical, the risk of GVHD increases. Prospective CD31 typing may reduce the risk of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8532023     DOI: 10.1056/NEJM199602013340502

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

Review 1.  Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies.

Authors:  F Andreotti; I Porto; F Crea; A Maseri
Journal:  Heart       Date:  2002-02       Impact factor: 5.994

2.  Association between genetic variants in adhesion molecules and outcomes after hematopoietic cell transplants.

Authors:  B Thyagarajan; S Jackson; S Basu; P Jacobson; M D Gross; D J Weisdorf; M Arora
Journal:  Int J Immunogenet       Date:  2012-05-30       Impact factor: 1.466

3.  CD31 signals confer immune privilege to the vascular endothelium.

Authors:  Kenneth Cheung; Liang Ma; Guosu Wang; David Coe; Riccardo Ferro; Marco Falasca; Christopher D Buckley; Claudio Mauro; Federica M Marelli-Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-09-21       Impact factor: 11.205

4.  The alleles of PECAM-1.

Authors:  Melanie S Novinska; Bradley C Pietz; Thomas M Ellis; Debra K Newman; Peter J Newman
Journal:  Gene       Date:  2006-04-11       Impact factor: 3.688

Review 5.  The biology of PECAM-1.

Authors:  P J Newman
Journal:  J Clin Invest       Date:  1997-01-01       Impact factor: 14.808

6.  Leucine125Valine (Leu125Val) Gene Polymorphism of Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1) and Myocardial Infarction in Indian Population.

Authors:  Kavita K Shalia; Manoj R Mashru; Surendra L Soneji; Vinod K Shah; Satchidanand Payannavar; Amar Walvalkar; Rajashree A Mokal; Shilpa M Mithbawkar; Ketki V Kudalkar; Ajin Abraham; Priti K Thakur
Journal:  Indian J Clin Biochem       Date:  2010-08-25

7.  CD31 exhibits multiple roles in regulating T lymphocyte trafficking in vivo.

Authors:  Liang Ma; Kenneth C P Cheung; Madhav Kishore; Sussan Nourshargh; Claudio Mauro; Federica M Marelli-Berg
Journal:  J Immunol       Date:  2012-09-10       Impact factor: 5.422

8.  A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms.

Authors:  Carolina Martínez-Laperche; Elena Buces; M Carmen Aguilera-Morillo; Antoni Picornell; Milagros González-Rivera; Rosa Lillo; Nazly Santos; Beatriz Martín-Antonio; Vicent Guillem; José B Nieto; Marcos González; Rafael de la Cámara; Salut Brunet; Antonio Jiménez-Velasco; Ildefonso Espigado; Carlos Vallejo; Antonia Sampol; José María Bellón; David Serrano; Mi Kwon; Jorge Gayoso; Pascual Balsalobre; Álvaro Urbano-Izpizua; Carlos Solano; David Gallardo; José Luis Díez-Martín; Juan Romo; Ismael Buño
Journal:  Blood Adv       Date:  2018-07-24

9.  Establishment of in vitro cellular model predicting histocompatibility in allograft.

Authors:  Y Hao; X Wu; Z Liang; P Xiong; X Jiang; F Gong
Journal:  J Tongji Med Univ       Date:  2001

10.  Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation.

Authors:  Joseph McGuirk; Gang Hao; Weijian Hou; Sunil Abhyankar; Casey Williams; Weisi Yan; Jianda Yuan; Xiuqin Guan; Robert Belt; Shaun Dejarnette; Jeffery Wieman; Ying Yan
Journal:  J Hematol Oncol       Date:  2009-04-20       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.